1. Medtech Insight
  2. >>Policy & Regulation

Bill To Allow FDA To Destroy Counterfeit Devices Wins Praise On Hill; J&J Exec Testifies In Support

 
• By Sue Darcey

Several US House members are backing a new piece of legislation that would give the US Food and Drug Administration the authority to destroy counterfeit devices when they arrive at points of entry into the country. A Johnson & Johnson executive who specializes in global brand protection provided dramatic testimony before a House health panel on 29 January on the need for the anti-counterfeiting bill.

Capitol-building-dome-light

Medtech counterfeiters are endangering the lives of US patients with their illicit trade in counterfeit devices to American hospitals, and Congress could assist by giving the Food and Drug Administration the authority to destroy the fakes, a Johnson & Johnson executive says.

“Lawmakers play a critical role in strengthening our nation’s laws to reduce incentives for engaging in illegal trade. As such,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By Elizabeth Orr

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.

MHRA’s Tallon Hails PMS Regulation As Start Of UK Device Framework Transformation

 
• By Ashley Yeo

16 June marked the first major new regulatory instrument in the UK’s post-Brexit transition to a standalone device regulatory system for Great Britain.

Increasing Safety Concerns Spur Scrutiny of Device Plastics Use

 
• By Elizabeth Orr

With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.